WHAT IS THE GCRC?

The GCRC is the major clinical research facility for Stanford University School of Medicine, and in the current year involves a total of 208 active protocols and 70 principal investigators from 32 clinical departments. Our goals are to provide an optimal facility for the conduct of patient oriented research, to translate basic scientific knowledge into a better understanding and treatment of human diseases, and to train health professionals in clinical research. Space in Stanford University Hospital provides an outstanding inpatient and outpatient GCRC facility, and a premature infant research program utilizes scatter beds in the adjacent Lucile Salter Packard Children's Hospital.

The eight major programs and investigators which form the core of the GCRC are as follows: (1) Recombinant Idiotype Vaccines for the Immunotherapy of Follicular Non-Hodgkin’s Lymphomas (R. Levy), (2) Clinical Trials in HIV Positive Patients (T. Merigan), (3) Surgery for Necrotizing Enterocolitis in Human Infants (L. Moss), (4) Studies of Hypothalamic-Pituitary-Adrenal Axis in Psychotic Depression (A. Schatzberg), (5) A Phase I Study of ZD1839 (Iressa) in Combination with Oxaliplatin, 5-Fluorouracil, and Leucovorin in Advanced Solid Malignancies (B. Sikic), (6) Clinical Experiment of H-Pylori Transmission (J. Parsonnet), (7) Pathophysiology of Hepatorenal Syndrome (B. Myers) and (8) Gene Therapy for Hemophilia (M. Kay and B. Glader).

Other current projects include: Coronary Heart Disease Risk Factors in Patients with Noninsulin Dependent Diabetes; Genetic Determinants of Human Hypertension; HPA Axis/Dopamine Interactions in Psychotic Depression; Influence of Dietary Intervention on Survival of Women with Breast Cancer; Transcranial Doppler Monitoring of Microemboli in Patients with Mechanical Heart Valve Replacements; Radioimmunotherapy of Cancers; Prevention of Type I Diabetes; and Effects of Smoking Cessation on Vascular Reactivity.